287 related articles for article (PubMed ID: 29634991)
21. Structure-based inhibitors of tau aggregation.
Seidler PM; Boyer DR; Rodriguez JA; Sawaya MR; Cascio D; Murray K; Gonen T; Eisenberg DS
Nat Chem; 2018 Feb; 10(2):170-176. PubMed ID: 29359764
[TBL] [Abstract][Full Text] [Related]
22. Computational Insights Into the Inhibition Mechanism of Proanthocyanidin B2 on Tau Hexapeptide (PHF6) Oligomer.
Li Q; Xiong C; Liu H; Ge H; Yao X; Liu H
Front Chem; 2021; 9():666043. PubMed ID: 34336783
[TBL] [Abstract][Full Text] [Related]
23. Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity.
Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
J Alzheimers Dis; 2016; 51(1):165-78. PubMed ID: 26836184
[TBL] [Abstract][Full Text] [Related]
24. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
25. Atomistic mechanism of polyphenol amyloid aggregation inhibitors: molecular dynamics study of Curcumin, Exifone, and Myricetin interaction with the segment of tau peptide oligomer.
Berhanu WM; Masunov AE
J Biomol Struct Dyn; 2015; 33(7):1399-411. PubMed ID: 25093402
[TBL] [Abstract][Full Text] [Related]
26. Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.
Wasiak T; Ionov M; Nieznanski K; Nieznanska H; Klementieva O; Granell M; Cladera J; Majoral JP; Caminade AM; Klajnert B
Mol Pharm; 2012 Mar; 9(3):458-69. PubMed ID: 22206488
[TBL] [Abstract][Full Text] [Related]
27. Can any "non-specific charge modification within microtubule binding domains of Tau" be a prerequisite of the protein amyloid aggregation? An in vitro study on the 1N4R isoform.
Jangholi A; Ashrafi-Kooshk MR; Arab SS; Karima S; Poorebrahim M; Ghadami SA; Moosavi-Movahedi AA; Khodarahmi R
Int J Biol Macromol; 2018 Apr; 109():188-204. PubMed ID: 29248553
[TBL] [Abstract][Full Text] [Related]
28. Interplay of isoform 1N4R tau protein and amyloid-β peptide fragment 25-35 in reducing and non-reducing conditions.
Mohammadi F; Takalloo Z; Rahmani H; Nasiri Khalili MA; Khajeh K; Riazi G; H Sajedi R
J Biochem; 2021 Feb; 169(1):119-134. PubMed ID: 32857841
[TBL] [Abstract][Full Text] [Related]
29. S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.
Zhang W; Du Y; Bai M; Xi Y; Li Z; Miao J
J Pept Sci; 2013 Mar; 19(3):159-65. PubMed ID: 23349038
[TBL] [Abstract][Full Text] [Related]
30. Effect of cellular polyanion mimetics on tau peptide aggregation.
Ismail T; Kanapathipillai M
J Pept Sci; 2018 Nov; 24(11):e3125. PubMed ID: 30251388
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action.
Sharma S; Nehru B; Saini A
Neurochem Int; 2017 Sep; 108():481-493. PubMed ID: 28652220
[TBL] [Abstract][Full Text] [Related]
32. Charge-pairing mechanism of phosphorylation effect upon amyloid fibrillation of human tau core peptide.
Inoue M; Hirata A; Tainaka K; Morii T; Konno T
Biochemistry; 2008 Nov; 47(45):11847-57. PubMed ID: 18922026
[TBL] [Abstract][Full Text] [Related]
33. Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitro.
Paranjape SR; Riley AP; Somoza AD; Oakley CE; Wang CC; Prisinzano TE; Oakley BR; Gamblin TC
ACS Chem Neurosci; 2015 May; 6(5):751-60. PubMed ID: 25822288
[TBL] [Abstract][Full Text] [Related]
34. Mapping the configurational landscape and aggregation phase behavior of the tau protein fragment PHF6.
Pretti E; Shell MS
Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2309995120. PubMed ID: 37983502
[TBL] [Abstract][Full Text] [Related]
35. Positional effects of phosphorylation on the stability and morphology of tau-related amyloid fibrils.
Inoue M; Konno T; Tainaka K; Nakata E; Yoshida HO; Morii T
Biochemistry; 2012 Feb; 51(7):1396-406. PubMed ID: 22304362
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent binding behavior of anthraquinone derivative purpurin interacting with tau-derived peptide protofibril.
Wu X; Zhu L; Wang G; Zhang Q; Qian Z
Phys Chem Chem Phys; 2023 Oct; 25(39):26787-26796. PubMed ID: 37781899
[TBL] [Abstract][Full Text] [Related]
37. Development of a Scalable, High-Throughput-Compatible Assay to Detect Tau Aggregates Using iPSC-Derived Cortical Neurons Maintained in a Three-Dimensional Culture Format.
Medda X; Mertens L; Versweyveld S; Diels A; Barnham L; Bretteville A; Buist A; Verheyen A; Royaux I; Ebneth A; Cabrera-Socorro A
J Biomol Screen; 2016 Sep; 21(8):804-15. PubMed ID: 26984927
[TBL] [Abstract][Full Text] [Related]
38. Characterization of two VQIXXK motifs for tau fibrillization in vitro.
Li W; Lee VM
Biochemistry; 2006 Dec; 45(51):15692-701. PubMed ID: 17176091
[TBL] [Abstract][Full Text] [Related]
39. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity.
Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
Neurodegener Dis; 2017; 17(2-3):73-82. PubMed ID: 27760426
[TBL] [Abstract][Full Text] [Related]
40. Selective Inhibition of Aggregation and Toxicity of a Tau-Derived Peptide using Its Glycosylated Analogues.
Frenkel-Pinter M; Richman M; Belostozky A; Abu-Mokh A; Gazit E; Rahimipour S; Segal D
Chemistry; 2016 Apr; 22(17):5945-52. PubMed ID: 26891276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
